IRVINE, Calif.--(BUSINESS WIRE)--Cobalis Corp. (OTC BB: CLSC), a pharmaceutical development company specializing in anti-allergy medications, today announced that it has completed the locking of the database for its pivotal twin Phase III Clinical Trials of PreHistin™ in seasonal allergic rhinitis. An independent contract research organization (CRO) will now begin the process of implementing the statistical analysis plan designed to analyze the data from the pivotal trials.
